

## REPLACEMENT SHEET

2. Use according to claim 1, wherein in formula (I) R<sub>1</sub> is hydrogen or methyl  
and/or R<sub>2</sub> is hydrogen or methyl and/or R<sub>4</sub> is hydroxy or R<sub>3</sub> and R<sub>4</sub> together are oxo  
5 and/or R<sub>5</sub> and R<sub>6</sub> are methyl.
3. Use according to claim 1, wherein the compound of formula (I) is  
trilostane, ketotrilostane or epostane.
- 10 4. Use according to any one of claims 1 to 3, wherein the angiotensin II related  
disease is a cardiovascular disease.
5. Use according to any one of the previous claims, wherein the angiotensin II  
related disease is congestive heart failure, post myocardial infarction,  
15 cardiomyopathy, diabetes, renal failure, metabolic syndrome (Syndrome X) or  
arrhythmia.
6. Use according to claim 4, wherein the cardiovascular disease is post  
myocardial infarction.
- 20 7. Use according to any one of the preceding claims, wherein the medicament is  
administered in an amount of from 0.5 to 4 mg/kg/day.
8. Use according to any one of claims 1 to 3, wherein the angiotensin II related  
25 disease is a proliferative disease.
9. Use according to claim 8, wherein the proliferative disease is peripheral  
arterial disease, cerebro vascular disease, cardiofibrosis, cardiac myopathy, diabetic  
retinopathy, diabetic gangrene, diabetic nephropathy, scleroderma, aneurism, asthma  
30 or atheroma.
10. Use according to claim 8 or claim 9, wherein the proliferative disease is  
cardiofibrosis.

2. Use according to claim 1, wherein in formula (I)  $R_1$  is hydrogen or methyl and/or  $R_2$  is hydrogen or methyl and/or  $R_4$  is hydroxy or  $R_3$  and  $R_4$  together are oxo and/or  $R_5$  and  $R_6$  are methyl.
- 5 3. Use according to claim 1, wherein the compound of formula (I) is trilostane, ketotrilostane or epostane.
4. Use according to any one of claims 1 to 3, wherein the angiotensin II related disease is a cardiovascular disease.
- 10 any one of the previous claims angiotensin II related
5. Use according to ~~claim 4~~, wherein the ~~cardiovascular~~ disease is congestive heart failure, post myocardial infarction, cardiomyopathy, diabetes, renal failure, metabolic syndrome (Syndrome X) or arrhythmia.
- 15 6. Use according to claim 4, wherein the cardiovascular disease is post myocardial infarction.
7. Use according to any one of the preceding claims, wherein the medicament is administered in an amount of from 0.5 to 4 mg/kg/day.
- 20 8. Use according to any one of claims 1 to 3, wherein the angiotensin II related disease is a proliferative disease.
9. Use according to claim 8, wherein the proliferative disease is peripheral
- 25 arterial disease, cerebro vascular disease, ~~atheroma~~ cardiofibrosis, cardiac myopathy, diabetic retinopathy, diabetic gangrene, diabetic neph<sup>r</sup>ropathy, scleroderma, aneurism, asthma or atheroma.
10. Use according to claim 8 or claim 9, wherein the proliferative disease is
- 30 cardiofibrosis.